Detalles de la búsqueda
1.
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
JTO Clin Res Rep;
3(10): 100406, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36247019
2.
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.
Future Oncol;
18(7): 781-791, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918546
3.
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Lung Cancer;
154: 176-185, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721611
4.
Crizotinib in Patients With MET-Amplified NSCLC.
J Thorac Oncol;
16(6): 1017-1029, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33676017
5.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.
Clin Cancer Res;
27(9): 2424-2429, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33563633
6.
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Pharmacoepidemiol Drug Saf;
30(6): 758-769, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428292
7.
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Drugs;
81(2): 257-266, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331989
8.
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Future Oncol;
17(1): 103-115, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32959703
9.
Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
Future Oncol;
16(36): 3107-3116, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32869649
10.
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
Lung Cancer;
145: 167-172, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32460197
11.
Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe.
Pharmacol Res Perspect;
8(2): e00570, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32232958
12.
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Nat Med;
26(1): 47-51, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31932802
13.
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Future Oncol;
16(1): 4289-4301, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778074
14.
Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer.
Future Oncol;
15(24): 2857-2871, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31298572
15.
Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.
Cancer Chemother Pharmacol;
84(1): 203-211, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31127319
16.
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.
J Thorac Oncol;
14(6): 1077-1085, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30822515
17.
Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.
Future Oncol;
15(10): 1097-1103, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30652510
18.
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
J Thorac Oncol;
13(10): 1539-1548, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29966800
19.
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
J Clin Oncol;
36(22): 2251-2258, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29768118
20.
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol;
36(14): 1405-1411, 2018 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29596029